Anthracycline Chemistry And Biology Ii

This series presents critical reviews of the present position and future trends in modern chemical research. It contains short and concise reports on chemistry, each written by the world renowned experts. The series is still valid and useful after five or ten years. More information as well as the electronic version of the whole content is available at: springerlink.com.

With contributions by numerous experts

This series presents critical reviews of the present position and future trends in modern chemical research. It contains short and concise reports on chemistry, each written by the world renowned experts. The series is still valid and useful after five or ten years. More information as well as the electronic version of the whole content is available at: springerlink.com.

Recent advances in precision medicine and immuno-oncology have led to highly specific and efficacious cancer therapies such as monoclonal antibodies and immune checkpoint inhibitors (ICIs). This book provides an up-to-date overview of advances in the field of immuno-oncology. Chapters cover such topics as ICIs and how they mount a robust immune response against cancer cells as well as the response of ICIs to treatment predictive biomarkers and their potential immune-related adverse events (irAEs). Additionally, the book includes a comprehensive review of the powerful FDA-approved therapeutic agent doxorubicin, highlighting the molecular mechanisms behind doxorubicin’s drug resistance and critical side effects.

The approach to drug discovery from natural sources has yielded many important new pharmaceuticals inaccessible by other routes. In many cases the isolated natural product may not be an effective drug for any of several reasons, but it nevertheless may become a drug through chemical modification or have a novel pharmacophore for future drug design. In summarizing the status of natural products as cancer chemotherapeutics, Anticancer Agents from Natural Products, Second Edition covers the: History of each covered drug—a discussion of its mechanism on action, medicinal chemistry, synthesis, and clinical applications Potential for novel drug discovery through the use of genome mining as well as future developments in anticancer drug discovery Important biosynthetic approaches to "unnatural" natural products Anticancer Agents from Natural Products, Second Edition discusses how complex target-oriented synthesis—enabled by historic advances in methodology—has enormously expanded the scope of the possible. This book covers the current clinically used anticancer agents that are either natural products or are clearly derived from natural product leads. It also reviews drug candidates currently in clinical development since many of these will be clinically used drugs in the future. Examples include the drugs etoposide and teniposide derived from the lead compound podophyllotoxin; numerous analogs derived from taxol; topotecan, derived from camptothecin; and the synthetic clinical candidates, E7389 and HTI-286, developed from the marine leads, halichondrin B and hemiasterlin.

Developed from a symposium at the 205th National Meeting of the ACS in Denver, March 1993, held to bring together researchers who are involved in the direct design and synthesis of new drugs with researchers who are investigating biochemical processes and mechanisms of action. The volume covers research relevant to the development of novel anthracyclines, such as the synthesis of promising new analogs, studies of mechanisms of action, and new approaches to improving properties for this class of compounds by using different drug- delivery and tumor-targeting systems. Annotation copyright by Book News, Inc., Portland, OR

Born out of a project of the IUPAC's committee on Medicinal Chemistry and Drug Development, this reference addresses past and current strategies for successful drug analog development, extending the previously published volume by nine new analog classes and eight case studies. Like its precursor, this volume also contains a general section discussing universally applicable strategies for analog discovery and development. Spanning a wide range of therapeutic fields and chemical classes, the two volumes together constitute the first systematic approach to drug analog development. Of interest to virtually every researcher working in drug discovery and pharmaceutical chemistry.

Knoevenagel Reaction of Unprotected Sugars, By M.-C. Scherrmann ; Carbohydrate-Based Lactones: Synthesis and Applications, By N. M. Xavier, A. P. Rauter, and Y. Queneau; Heterogeneously-Catalyzed Conversion of Carbohydrates, By K. De Oliveira Vigier and F. Jérôme; Palladium-Catalyzed Telomerization of Butadiene with Polyols: From Mono to Polysaccharides, By S. Bouquillon, J. Muzart, C. Pinel, and F. Rataboul; Monosaccharides, By J.A. Galbis and M.G. García-Martín; Natural Sources, By L. Weignerová and V. Křen; Synthesis and Applications of Ionic Liquids Derived from Natural Sugars; By C. Chiappe, A. Marra, and A. Mele